JOIN US AT INS
17th World Congress
of the International Neuromodulation Society
Lisbon, Portugal | 2026
May 9-12
00
Days
00
Hours
00
Minutes
00
Seconds
A SALUDA MEDICAL SIGNATURE RECEPTION
Join us for a reception to learn how the Evoke® System with EVA™ Sensing Technology is moving SCS forward.
Monday, 11 May
19:00 – 23:00
Rua Jaú 54, 1300-314 Lisbon Portugal
FACULTY
Jason Pope, MD
Harold Nijhuis, MD
Jenny Jennings
Jarek Maciaczyk, MD
Meet the Evoke® System
Disrupting pain by removing guesswork.
- Listen to the spinal cord, not the representative
The dose is anchored to each patient’s individual physiology – unlike others that are set subjectively by the programmer. - Therapy is individually calibrated from the start
Objectively scans and analyzes each patient’s unique spinal cord to identify therapeutic settings from day one of the trial phase. - Automatically adjusts to maintain consistent pain relief
Continual adjustments address both over AND under dosing for sustainable, predictable pain relief.
TRADESHOW BOOTH
Visit us at booth #01
Interact with Saluda experts and discover more about the Evoke® System, now elevated by EVA™ Sensing Technology, and learn more about our life-changing technology.
Networking Lounge
Barista Zone
Saluda Experts
key podium presentations
Five years of closed-loop spinal cord stimulation: a retrospective study of 118 patient outcomes with an 84% device retention and a 2.5% infection rate
Monday, 11 May
17:45 – 17:55
Auditorium I
PRESENTER:
Amin Elkhatim Elyass, MD
ECAP Dose-Controlled Closed-Loop SCS for complex regional pain syndrome: a subgroup analysis of the ECAP Study
Monday, 11 May
17:55 – 18:05
Auditorium I
PRESENTERS
Salim Hayek, MD
Long-term ECAP Dose-Controlled Closed-Loop Therapy Outcomes in Same Day Objective SCS Trial Responders: 12-Month Results
Tuesday, 12 May
16:40 – 16:50
Auditorium II
PRESENTER:
Jason Pope, MD
An In-depth Analysis of the Therapeutic Effects of ECAP Dose-Controlled Closed Loop SCS During the Trial Period
Tuesday, 12 May
17:00 – 17:10
Auditorium II
PRESENTERS:
Björn Carsten Schultheis, MD
Dose Ratio Guidance in Spinal Cord Stimulation: Methodological Considerations
Tuesday, 12 May
17:10 – 17:20
Auditorium III IV
PRESENTER:
Jan Willem Kallewaard, MD
Therapeutic Neural Activation and the Prevention of Over- and Under-Stimulation: ECAP Study Sub-Analysis
Tuesday, 12 May
17:20 – 17:30
Auditorium III IV
PRESENTERS:
Jason Pope, MD
Optimal dose-response and patient-reported outcomes in CRPS treated with ECAP-controlled closed-loop SCS
Thursday, 14 May
11:00 – 11:10
Auditorium III IV
PRESENTER:
Eline van Lange, MD
SELECTED ABSTRACTS
Chhabra
Efficacy of Closed‑Loop Spinal Cord Stimulation Therapy in the Management of Post Herpetic Neuralgia – A Case Report
Goree
ECAP Dose‑Controlled Closed‑Loop SCS for painful diabetic neuropathy: subgroup analysis of the ECAP Study
Havenbergh
ECAP‑Based Neurophysiological Evaluation During Medication Tapering: A Prospective Study
Hanssens
Neural Dosing using a Next‑Generation, Automated, Advanced Sensing Platform Parallels Maximum Analgesia Requirements
Hanssens
Assessment of Neural Activation Accuracy, Pain Relief and QoL in Patients with Closed‑Loop Spinal Cord Stimulation (CL‑SCS) Therapy
Hayek
ECAP Dose‑Controlled Closed‑Loop SCS for complex regional pain syndrome: a subgroup analysis of the ECAP Study
Hunter
ECAP Dose‑Controlled Closed‑Loop SCS for chronic non‑surgical refractory back pain: subgroup analysis from two prospective multicenter clinical trials
Kallewaard
Neural Panel Study: Interim analysis of a Next‑Generation, Automated Programming Platform with Advanced Sensing Technology
Kallewaard
Dose Ratio Guidance in Spinal Cord Stimulation: Methodological Considerations
Ladner
Beyond the Evoked Compound Action Potential (ECAP): Characterization of Epidural Electrophysiological Signals in Preclinical Models of Spinal Cord Stimulation
Maciaczyk
Raynaud’s Phenomenon: Neurophysiological Insights using ECAP Dose‑Controlled Closed‑Loop SCS
Minkelis
Assessment of Neurophysiological Correlates of Maximal Analgesia with ECAP Dose‑Controlled Closed‑Loop SCS Observations from Triangle Pain Clinic
Mugan
Mind the Gap: Translational Challenges in Preclinical Spinal Cord Stimulation Models
Nikolic
Maximum Analgesic Effect using ECAP Dose‑Controlled Closed‑Loop SCS: Retrospective Analysis from the Multicenter, Real‑World DR Study
Nijhuis
Real‑World Outcomes using a Next‑Generation, Automated Programming Platform with Advanced Sensing Technology
Petersen
Sensing and Measuring Physiologic Responses to Stimulation using a Novel Paddled SCS Lead in a Porcine Model
Pope
Long‑term ECAP Dose‑Controlled Closed‑Loop Therapy Outcomes in Same Day Objection SCS Trial Responders: 12‑Month Results
Pope
Therapeutic Neural Activation and the Prevention of Over‑ and Under‑Stimulation: ECAP Study Sub‑Analyses
Schultheis
An In‑depth Analysis of the Therapeutic Effects of ECAP Dose‑Controlled Closed‑Loop SCS During the Trial Period
Thomson
Holistic Treatment Response in a Real‑world Chronic Pain Population Using ECAP‑Controlled Closed‑Loop SCS: 24‑month Outcomes Of the PMCF Study
Versantvoort
Preclinical Insights into ECAP‑guided Spinal Cord Stimulation: The Critical Role of Dorsal Column Activation in Neuropathic Pain Control
Versantvoort
ECAP Threshold Estimation in Preclinical SCS: Effects of Physiological, Methodological, and Technical Factors